Expression of miR-15a-5p, miR-17-5p, and miR-103-3p in hypertension-associated chronic kidney disease and hemodialysis patients

BackgroundMicroRNAs (miRs), which can be released into the extracellular environment, are important modulators of how cells react to a variety of stimuli. Prior research in the past ten years has concentrated on miRs as new clinical targets or diagnostic tools. Numerous studies on chronic kidney disease (CKD) have focused on miRs. One prevalent risk factor for CKD is hypertension (HTN), which damages targeted organs, including the kidneys, heart, and arteries.ObjectiveOur goal was to investigate the expressions of miRs (17-5p, 15a-5p, and 103-3p) in prerenal failure and renal failure patients under hypertension conditions, as these could be biomarkers of kidney damage caused by hypertension.Patients and methodsQuantitative real-time polymerase chain reaction (RT-PCR) was utilized to assess the expression levels of the above-mentioned miRs. A total of 110 studied cases that met the eligibility criteria of HTN-associated CKD were grouped into a pre-renal failure group (n = 50) and a renal failure group (n = 60), which included end-stage renal disease cases under hemodialysis beside 40 healthy controls.Results and conclusion Our research revealed that miR-103-3p was upregulated; however, miRs (15a-5p and 17-5p) were significantly downregulated in studied HTN-CKD groups compared with control subjects. The degree of deregulation correlated with the severity of the disease suggests that these miRs may be involved in the pathophysiology of HTN-related CKD, which in turn encourages additional research into their possible clinical use in the prevention and management of CKD. Moreover, these miRs showed areas under the curve near to 1 in receiver operating characteristics (ROC) analysis. Consequently, they might be used as markers for CKD.